

# QRS Tip Clotting Cascade Medications

Class	Generic Name	Brand Name	Actions/Indications
<b><u>Anticoagulants</u></b> <b>(IV or Subcutaneous)</b>	Unfractionated heparin	Heparin IV	Stroke prevention in Afib, PE, DVT. Used in all ACS,
Low Molecular Weight Heparin	Enoxaparin SC Dalteparin SC	Lovenox Fragmin	Same as above
Factor Xa Inhibitor	Fondaparinux SC	Arixtra	Alternative to enoxaparin: less bleeding than enox. Safe alternate in HIT
Direct Thrombin Inhibitor	Bivalirudin IV	Angiomax	ACS going for PCI, safe alternate in HIT
<b><u>Anticoagulants - Oral</u></b>			
Vitamin K antagonist	Warfarin	Coumadin	Must monitor INR. Non-valvular Afib-INR target 2.5

# Clotting Cascade Medications

Class	Generic Name	Brand Name	Actions/Indications
<b><u>Anticoagulants - Oral</u></b>			
Factor Xa inhibitors New/Novel Oral AntiCoagulants (NOACs = DOACs)	Dabigatran Apixaban Rivaroxaban Edoxaban	Pradax Eliquis Xarelto Lixiana	Non-Valvular Afib, VTE, PE
<b><u>Antiplatelet - Oral</u></b> <b>Platelet Inhibition</b>	Acetylsalicylic Acid Aspirin & Dipydrimole	Aspirin Aggrenox	CAD, ACS Secondary prevention of TIA or CVA
	Clopidogrel	Plavix	ACS, PCI
	Ticagrelor	Brilinta	ACS, PCI Note: ECASA to be 100mg or less. Higher doses may lessen effect of Ticagrelor
	Prasugrel	Effient	ACS, PCI

# Clotting Cascade Medications

Class	Generic Name	Brand Name	Actions/Indications
<p><b><u>Platelet Inhibition: con't</u></b> (Antiplatelet)</p>			
<p>GP IIb/IIIa inhibitors - IV</p>	<p>Abxicimab Tirofiban Eptifibatide</p>	<p>Reopro Aggrastat Integrelin</p>	<p>Potent platelet inhibitor in ACS after angioplasty with or without stent placement. Unstable ACS waiting for PCI</p>
<p><b><u>Fibrinolytic</u></b></p>	<p>Streptokinase Alteplase Retepase Tenecteplase</p>	<p>t-PA r-PA TNKase</p>	<p>Stroke, STEMI, PE  STEMI, PE</p>

# 2020 Thrombosis Canada Guidelines

**Heparin Induced Thrombocytopenia:** [https://thrombosiscanada.ca/wp-content/uploads/2020/02/Heparin-Induced-Thrombocytopenia\\_16Feb2020.pdf](https://thrombosiscanada.ca/wp-content/uploads/2020/02/Heparin-Induced-Thrombocytopenia_16Feb2020.pdf)

**Anticoagulation in Patients requiring Antiplatelet Therapy:** <https://thrombosiscanada.ca/wp-content/uploads/2019/12/Anticoagulation-in-patients-requiring-antiplatelet-therapy-2019Feb02-V2.pdf>

**Comparison of various NOACS/DOACs:** [https://thrombosiscanada.ca/wp-content/uploads/2020/02/NOACs-DOACs-Comparison-and-FAQs\\_16Feb2020.pdf](https://thrombosiscanada.ca/wp-content/uploads/2020/02/NOACs-DOACs-Comparison-and-FAQs_16Feb2020.pdf)

**Management of Bleeding with DOACs:** <https://thrombosiscanada.ca/wp-content/uploads/2019/04/NOACs-DOACs-Management-Bleeding-29Mar19.pdf>

**Elective Perioperative Management with DOACs:** <https://thrombosiscanada.ca/wp-content/uploads/2019/05/NOACs-DOACs-Perioperative-Management.pdf>

**Perioperative Management with Antiplatelet Therapy:** <https://thrombosiscanada.ca/wp-content/uploads/2019/02/Perioperative-Management-of-Antiplatelet-Therapy-2019-February-11.pdf>